TerrAscend Corp. (OTCMKTS:TRSSF - Get Free Report)'s share price dropped 9.1% on Thursday . The company traded as low as $0.50 and last traded at $0.50. Approximately 590,407 shares changed hands during mid-day trading, an increase of 351% from the average daily volume of 131,026 shares. The stock had previously closed at $0.55.
TerrAscend Price Performance
The stock has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.94. The company has a current ratio of 0.73, a quick ratio of 0.40 and a debt-to-equity ratio of 0.55.
TerrAscend Company Profile
(
Get Free Report)
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TerrAscend, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.
While TerrAscend currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
